BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fangbin Z, Xiang G, Liang D, Hui L, Xueding W, Baili C, Huichang B, Yinglian X, Peng C, Lizi Z. Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study (Baltimore). Medicine. 2016;95:e3326. [PMID: 27082580 DOI: 10.1097/md.0000000000003326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR, Krajinovic M, Ansari M. Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci 2016;17:E1502. [PMID: 27618021 DOI: 10.3390/ijms17091502] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
2 de Carvalho OV, Félix DM, de Camargo Tozato C, Fietto JLR, de Almeida MR, Bressan GC, Pena LJ, Silva-Júnior A. 6-methylmercaptopurine riboside, a thiopurine nucleoside with antiviral activity against canine distemper virus in vitro. Virol J 2017;14:124. [PMID: 28651549 DOI: 10.1186/s12985-017-0785-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Wang HH, He Y, Wang HX, Liao CL, Peng Y, Tao LJ, Zhang W, Yang HX. Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(8): 941-948 [PMID: 29491687 DOI: 10.3748/wjg.v24.i8.941] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
4 Zalizko P, Stefanovics J, Sokolovska J, Paramonova N, Klavina E, Erts R, Rovite V, Klovins J, Pukitis A. Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population. Therap Adv Gastroenterol 2020;13:1756284820937426. [PMID: 32704308 DOI: 10.1177/1756284820937426] [Reference Citation Analysis]
5 Pospisilova K, Siroka J, Karaskova E, Hradsky O, Lerchova T, Zarubova K, Copova I, Gonsorcikova L, Velganova-Veghova M, Francova I, Urbanek L, Geryk M, Mihal V, Bronsky J. Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study. Paediatr Drugs 2021;23:183-94. [PMID: 33709340 DOI: 10.1007/s40272-021-00439-1] [Reference Citation Analysis]
6 Yeo J, Woo HS, Lee SM, Kim YJ, Kwon KA, Park DK, Kim JH, Kim KO, Chung JW. Drug-induced eosinophilic pneumonia in a patient with Crohn's disease: diagnosis and treatment using fraction of exhaled nitric oxide. Intest Res. 2017;15:529-534. [PMID: 29142522 DOI: 10.5217/ir.2017.15.4.529] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ding L, Zhang FB, Liu H, Gao X, Bi HC, Huang L, Wang XD, Chen BL, Zhang Y, Lv C, Hu PJ, Huang M. Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients. Pharmacol Res Perspect 2021;9:e00764. [PMID: 33929082 DOI: 10.1002/prp2.764] [Reference Citation Analysis]
8 Sousa P, Estevinho MM, Dias CC, Ministro P, Kopylov U, Danese S, Peyrin-Biroulet L, Magro F. Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. J Clin Med 2020;9:E2216. [PMID: 32668748 DOI: 10.3390/jcm9072216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]